SGLT2i in CKD with high albuminuria: an observational real-world study

被引：0
|
作者：
Svensson, Maria K. [1 ]
Bodegard, Johan [2 ]
Thuresson, Marcus [3 ]
Ambery, Philip [2 ]
机构：
[1] Uppsala Univ, Uppsala, Sweden
[2] AstraZeneca, Gothenburg, Sweden
[3] Statisticon AB, Uppsala, Sweden
来源：
NEPHROLOGY DIALYSIS TRANSPLANTATION | 2024年 / 39卷
关键词：
D O I：
10.1093/ndt/gfae069.147
中图分类号：
R3 [基础医学]; R4 [临床医学];
学科分类号：
1001 ; 1002 ; 100602 ;
摘要：
2638
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Efficacy, renal safety and tolerability of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in elderly patients with type 2 diabetes: A real-world experience
    Tumminia, Andrea
    Graziano, Marco
    Vinciguerra, Federica
    Lomonaco, Andrea
    Frittita, Lucia
    PRIMARY CARE DIABETES, 2021, 15 (02) : 283 - 288
  • [32] SGLT2i treatment at the beginning of real time exposure in a HFrEF population
    Vintila, V.
    Ciocanel, A.
    Stamate, E.
    Vintila, A. M.
    Vinereanu, D.
    EUROPEAN JOURNAL OF HEART FAILURE, 2024, 26 : 251 - 251
  • [33] Changes in SGLT2i and GLP-1RA real-world initiator profiles following cardiovascular outcome trials: A Danish nationwide population-based study
    Knudsen, Jakob S.
    Baggesen, Lisbeth M.
    Lajer, Maria
    Nurkanovic, Larisa
    Ustyugova, Anastasia
    Sorensen, Henrik T.
    Thomsen, Reimar W.
    PLOS ONE, 2020, 15 (03):
  • [34] Combined therapy with SGLT2i and GLP-1ra improves cardiovascular prognosis in a population with diabetes and overweigh or obesity. A real-world clinical practice study
    Garcia Vega, D.
    Cinza-Sanjurjo, S.
    Gonzalez-Juanatey, J. R.
    Eiras, S.
    EUROPEAN HEART JOURNAL, 2023, 44
  • [35] SGLT2i and postglomerular vasodilation reply
    van Bommel, Erik J. M.
    van Raalte, Daniel H.
    KIDNEY INTERNATIONAL, 2020, 97 (04) : 806 - 806
  • [36] Seven suggestions for successful SGLT2i use in glomerular disease-a standalone CKD therapy?
    McQuarrie, Emily P.
    Gillis, Keith A.
    Mark, Patrick B.
    CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2022, 31 (03): : 272 - 277
  • [37] Combined sodium-glucose-transporters inhibitors (SGLT2i) and glucagon-like-peptide receptor agonist (GLP1ra) compared with SGLT2i or GLP1ra alone improves survival: a Real-World Registry
    Vega, D. Garcia
    Cinza-Sanjurjo, S.
    Eiras, S.
    Gonzalez-Juanatey, J. R.
    EUROPEAN HEART JOURNAL, 2024, 45
  • [38] SGLT2 inhibitors improve plasma atherogenic biomarkers in patients with type 2 diabetes: a real-world retrospective observational study
    Imre, Eren
    Gunhan, Hatice G.
    Erel, Pinar
    Ustay, Ozlem
    MINERVA ENDOCRINOLOGY, 2023, 48 (03): : 295 - 304
  • [39] Combined sodium-glucose-transporters inhibitors (SGLT2i) and glucagon-like-peptide receptor agonist (GLP1ra) compared with SGLT2i or GLP1ra alone improves survival: a Real-World Registry
    Vega, D. Garcia
    Cinza-Sanjurjo, S.
    Eiras, S.
    Gonzalez-Juanatey, J. R.
    EUROPEAN HEART JOURNAL, 2024, 45
  • [40] SGLT2i Use in Pediatric Heart Failure: Multicenter Study
    Butts, R.
    Nandi, D.
    Hong, B.
    Lorts, A.
    Profita, E.
    Spinner, J.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2024, 43 (04): : S149 - S149
12345